FHI Clinical Announces Intent to Acquire TCD


FHI Clinical Inc. has announced its intent to acquire Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South African-based CRO and a subsidiary of EOH. With this transaction, FHI Clinical will employ more than 425 global staff representing 12 countries. 

Headquartered in Centurion (Gauteng), South Africa, TCD has access to the South African market. South Africa accounts for most of the clinical trial activity in sub-Saharan Africa with the majority being infectious disease therapeutic studies. With approximately 285 employees already based in East and West Africa, FHI Clinical sees a unique opportunity to further expand its share of the ID market.

Current studies in TCD’s portfolio include both innovative vaccines and treatments spanning all phases of clinical research from single-dose Phase I trials to large multi-site Phase III and Phase IV trials.

FHI Clinical Announces Intent to Acquire South African-Based Triclinium Clinical Development (TCD)

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.